New inhaled treatment aims to get ICU patients off ventilators faster
NCT ID NCT07317050
First seen Jan 11, 2026 · Last updated May 16, 2026 · Updated 19 times
Summary
This study tests whether an inhaled drug called aprotinin can help adults with moderate to severe acute respiratory distress syndrome (ARDS) recover faster. About 156 critically ill patients in intensive care will receive either aprotinin or a placebo, plus standard care. The main goal is to see if aprotinin increases the number of days patients are free from a breathing machine and improves survival within 28 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital General Universitario de Ciudad Real
Ciudad Real, Ciudad Real, 13005, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.